정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1003 | Completed | Nebulized Heparin for the Treatment of COVID-19 | Pneumonia, Viral | Drug: Heparin Drug: 0.9%sodium chloride |
Phase 4 | Frederick Health | OTHER | 50 | All | 18 Years | Frederick Health Hospital, Frederick, Maryland, United States |
| 1002 | Enrolling by invitation | Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury | Acute Lung Injury | Drug: Heparin Drug: 0.9% Sodium-chloride |
Phase 4 | Frederick Health | OTHER | 50 | All | 18 Years | Frederick Health Hospital, Frederick, Maryland, United States |
| 1001 | Recruiting | Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19 | Pneumonia | Drug: Heparin sodium Drug: Enoxaparin |
Phase 4 | Clinica San Camilo, Argentina | OTHER | 200 | All | 18 Years ~ 100 Years | Clinica San Camilo, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina |
| 1000 | Active, not recruiting | Nebulized PL for Post-COVID-19 Syndrome | Covid19 | Biological: Nebulized Platelet Lysate Other: Nebulized Sterile Saline |
Not Applicable | Regenexx, LLC | INDUSTRY | 1 | All | 18 Years ~ 85 Years | Centeno-Schultz Clinic, Broomfield, Colorado, United States |
| 999 | Not yet recruiting | NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia | COVID-19 Pneumonia | Biological: NestaCell® Biological: Placebo |
Phase 2 | Azidus Brasil, Cellavita Pesquisa Cientifica Ltda, Hospital Vera Cruz | INDUSTRY | 90 | All | 18 Years | Hospital Vera Cruz, Campinas, Sao Paulo, Brazil Hospital de Barueri, Sao Paulo, Brazil IncCOR, Sao Paulo, Brazil UNIFESP, Sao Paulo, Brazil |
| 998 | Terminated | Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection | Encephalitis | Biological: blood samples | Not Applicable | Centre Hospitalier de PAU | OTHER | 2 | All | 18 Years | CH de Pau, Pau, France |
| 997 | Not yet recruiting | New Antiviral Drugs for Treatment of COVID-19 | Drug Effect | Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : | Phase 3 | Mansoura University | OTHER | 100 | All | 12 Years | Mansoura University, Mansoura, Select A State Or Province, Egypt |